According to The New England Journal of Medicine, approximately 800,000 knee and hip replacement procedures are performed annually in the United States, and complications related to infections occur in approximately 2 percent of those procedures.
Under terms of the agreement, Abbott and GenLab will develop and commercialize the new assay for use on the PLEX-ID automated microbial identification system. In the United States, PLEX-ID is currently intended only for non-diagnostic use, but assays are now being developed for future clinical diagnostic uses. PLEX-ID is capable of generating diagnostic results within five to six hours, compared to other methods that may take several days.
Related Articles on Infections:
Kansas Hospitals Reduce Bloodstream Infections by 38%
Banner Hospitals Implement Patient Emergency Hotline to Increase Safety, Satisfaction
California Healthcare Institute Report Spotlights Need for Antibiotics Research
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.